Doug Buchanan

Doug Buchanan, B.Sc., M.Sc., MBA, has over 40 years’ experience in strategic and operational management as a leader in the healthcare industry and other sectors. Most recently, he was a Senior Vice President at LifeLabs Medical Laboratory Services, the largest diagnostics lab in Canada providing 100 million diagnostic tests each year, where he was responsible for strategy management, public relations, community engagement, and internal communications. Doug joined LifeLabs in 2013 as Senior Integration Officer following the acquisition of BC Biomedical Laboratories where he was the Chief Executive Officer responsible for this diagnostic lab services company with 45 patient service centers and more than 750 employees. Doug has also served as a Partner at Price Waterhouse Management Consultants, EVP Marketing of The WATCOM Group Inc., and VP Consulting Services Group at Sandwell Inc. He is an Institute-Certified Director from the Institute of Corporate Directors and has served on a number of non-profit and corporate boards of directors. Doug earned a Bachelors in Physics, Masters in Biology, and an MBA, all with honours, from the University of British Columbia.

Don M. Enns

Don Enns has been a senior executive and leader in the life sciences industry for over 30 years, building companies that provide analytical testing, clinical, development, and manufacturing services to the environmental, pharmaceutical, biotechnology, petrochemical, and food industries globally. He is currently the Vice President and Head of Drug Delivery Services at Evonik, one of the world’s leading specialty chemicals companies, with over €14 billion in annual revenue. Before this, Enns was President and CEO of TRANSFERRA Nanosciences Inc. (formerly Northern Lipids Inc.), which specialized in the development and manufacture of complex drug delivery systems using lipid nanoparticle science for small molecules, peptides, proteins, mRNA, siRNA, and DNA oligonucleotides. The company was acquired by Evonik in 2016.

Prior to his tenure at TRANSFERRA Nanosciences, Enns served as President of LifeSciences BC, a non-profit, industry association which supports and represents the life science community of British Columbia thought leadership, investment, advocacy, and promotion. Previously, he was also President and CEO of CANTEST Ltd., a BC-headquartered organization providing professional analytical and clinical services to support the environmental quality, pharmaceutical, biotechnology, and food safety industries. CANTEST Ltd. was acquired by Maxxam Analytics International Corp. (an OMERS owned company) in 2009.

Enns serves as chair of the NanoMedicines Innovation Network (NMIN), which brings together 60 principal investigators from 17 institutions across Canada with 15 companies and 8 not-for-profit research institutions to expand Canada’s position as a leader in nanomedicines R&D. In addition, he was a director for World Wildlife Fund, BC Advantage Fund, and an advisor to a number of different academic faculties and organizations such as Canada’s National Research Council. Formerly he also held director positions for BC Clinical Research Infrastructure Network, Genome BC, Kinexus Bioinformatics Corporation, Canadian Association of Laboratory Accreditation, and B.C. Water and Waste Association.

Enns earned his Bachelor of Science in Chemistry from Trinity Western University and his Masters in Business Administration from the University of British Columbia.

Brad Popovich

Brad Popovich is the former Chief Scientific Officer at Genome British Columbia in Vancouver BC (2011-present). His involvement in the organization spans many years; Brad sat on the board of directors from 2006-2011. He also acted as chair for the Science Committee at Genome British Columbia from 2008-2010. Outside his present role at Genome BC, Brad serves as Chairman, Genetic Information Management Systems, and Director, Centre for Drug Research and Development Ventures (CVI) and Centre for Drug Research and Development (CDRD).

Brad was the President and Chief Executive Officer of Sirius Genomics from 2006-2009 and was the Vice President of Operations at Xenon Pharmaceuticals (2001-2005). Previously, he was the Founder and Director to the Molecular Diagnostics Laboratory at Oregon Health Sciences University where he was also the Director of Graduate Education and the Executive Director, Genetic Service Laboratories at the University Hospital (1992-2001). Brad was previously the Founder and Director of the DNA Diagnostic Laboratory at Children’s Hospital San Diego / University of California San Diego (1989-1992).

Previously Brad served as a Director for: Sirius Genomics (2006-2012); DNA Direct (2005-2010); Tm Bioscience (2003-2006); the American College of Medical Genetics (Director and VP Laboratory Genetics 1999-2005); and the American College of Medical Genetics Foundation (1999-2005). He additionally Chaired the Oregon Genetic Privacy Advisory Committee (1995-2001) and was a founding member of the Oregon DNA Forensic Experts Panel (1993-2001).

Brad’s genetic training is in genetic counselling (MS, Sarah Lawrence College) biochemical genetics (MSc, McGill University), molecular genetics (PhD, McGill University), and postdoctoral training / clinical fellowship (University of Wisconsin, and University of North Carolina (laboratory of Nobel Laureate Oliver Smithies). He became board certified in clinical molecular genetics in 1993 by the American Board of Medical Specialists and the American Board of Medical Genetics.

Mike Fannon

Mike Fannon is the Founder and CEO of BioIT Solutions, a company specializing in advanced computational, workflow and data management systems for biotechnology research, clinical diagnostics and drug development. Mike advises emerging biotechnology companies in business strategy, customer relationship management, laboratory automation and IT management. He is the chief architect of BioIT’s 1Platform4 software that captures, presents, and analyzes information along the full biotech product lifecycle. Previously, Mike was Vice President and Chief Information Officer of Human Genome Sciences, where he and his team designed computerized systems to manage HGS’s high-volume labs, R&D functions, product development and clinical trials. Mike earned an MBA in Operations Analysis from The American University, and a Bachelors degree in Physics from Rollins College in Winter Park, Florida.